# To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2

> **NCT05200741** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 150 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** DelNS1-2019-nCoV-RBD-OPT1
- **BIOLOGICAL:** Matching placebo

## Key facts

- **NCT ID:** NCT05200741
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-08
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200741, "To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05200741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*